Li Yi-Ping, Van Pham Long, Uzcategui Nathalie, Bukh Jens
Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Hvidovre Hospital, Hvidovre, Denmark; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark.
Institute of Human Virology and Key Laboratory of Tropical Disease Control of Ministry of Education, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou 510080, PR China.
J Gen Virol. 2016 Jun;97(6):1381-1394. doi: 10.1099/jgv.0.000445. Epub 2016 Mar 2.
MicroRNA 122 (miR-122) stimulates the replication and translation of hepatitis C virus (HCV) RNA by binding to two adjacent sites, S1 and S2, within the HCV 5'UTR. We demonstrated previously that the miR-122 antagomir miravirsen (SPC3649) suppresses the infection of HCV strain JFH1-based recombinants with HCV genotypes 1-6 5'UTR-NS2 in human hepatoma Huh7.5 cells. However, specific S1 mutations were permitted and conferred virus resistance to miravirsen treatment. Here, using the J6 (genotype 2a) 5'UTR-NS2 JFH1-based recombinant, we performed reverse-genetics analysis of S1 (ACACUCCG, corresponding to miR-122 seed nucleotide positions 8-1), S2 (CACUCC, positions 7-2), and ACCC (positions 1-4) at the 5' end of the HCV genome (5'E); the CC at positions 2-3 of 5'E is involved in miR-122 binding. We demonstrated that the 5'E required four nucleotides for optimal function, and that G or A at position 3 or combined GA at positions 2-3 of 5'E was permitted. In S1 and S2, several single mutations were allowed at specific positions. A UCC → CGA change at positions 4-3-2 of S1, S2, or both S1 and S2 (S1/S2), as well as a C → G change at position 2 of S1/S2 were permitted. We found that 5'E mutations did not confer virus resistance to miravirsen treatment. However, mutations in S1 and S2 induced virus resistance, and combined S1 and/or S2 mutations conferred higher resistance than single mutations. Identification of miR-122 antagomir resistance-associated mutations will facilitate the study of additional functions of miR-122 in the HCV life cycle and the mechanism of virus escape to host-targeting antiviral approaches.
微小RNA 122(miR - 122)通过与丙型肝炎病毒(HCV)5'非翻译区(UTR)内的两个相邻位点S1和S2结合,刺激HCV RNA的复制和翻译。我们之前证明,miR - 122拮抗剂米拉维森(SPC3649)可抑制基于HCV JFH1株的重组体感染人肝癌Huh7.5细胞,这些重组体具有HCV 1 - 6基因型的5'UTR - NS2。然而,特定的S1突变是允许的,并使病毒对米拉维森治疗产生抗性。在此,我们使用基于J6(2a基因型)5'UTR - NS2 JFH1的重组体,对HCV基因组5'端(5'E)的S1(ACACUCCG,对应于miR - 122种子核苷酸位置8 - 1)、S2(CACUCC,位置7 - 2)和ACCC(位置1 - 4)进行了反向遗传学分析;5'E第2 - 3位的CC参与miR - 122结合。我们证明5'E需要四个核苷酸才能发挥最佳功能,并且5'E第3位的G或A或第2 - 3位的GA组合是允许的。在S1和S2中,特定位置允许几个单突变。S1、S2或S1和S2两者(S1/S2)的第4 - 3 - 2位的UCC→CGA变化以及S1/S2第2位的C→G变化是允许的。我们发现5'E突变并未使病毒对米拉维森治疗产生抗性。然而,S1和S2中的突变诱导了病毒抗性,并且S1和/或S2的联合突变比单突变赋予更高的抗性。鉴定与miR - 122拮抗剂抗性相关的突变将有助于研究miR - 122在HCV生命周期中的其他功能以及病毒逃避宿主靶向抗病毒方法的机制。